Bellicum Pharmaceuticals, Inc (BLCM)

Etorro trading 970x250
Bellicum Pharmaceuticals, Inc (BLCM) Logo

About Bellicum Pharmaceuticals, Inc

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company’s clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. It has collaboration and license agreements with Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas. Address: 2710 Reed Road, Houston, TX, United States, 77051

Bellicum Pharmaceuticals, Inc News and around…

Latest news about Bellicum Pharmaceuticals, Inc (BLCM) common stock and company :

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
14 Dec, 2021 FinancialContent

Gainers Galera Therapeutics (NASDAQ:GRTX) stock increased by 134.05% to $3.23 during Tuesday's pre-market session. ...

Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
13 Dec, 2021 Yahoo! Finance

HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2.5 million for continued listing of the company’s common stock. Ac

Sumitovant Biopharma Highlights Significant Clinical, Regulatory and Commercial Achievements Across its Portfolio of Companies in the Second Quarter of FY2021
10 Dec, 2021 Yahoo! Finance

Sumitovant Biopharma, Inc. today announced that its portfolio of four wholly-owned subsidiary companies (Urovant, Enzyvant, Altavant and Spirovant) and Myovant (NYSE: MYOV), a publicly listed company that is majority-owned by Sumitovant, achieved significant clinical, regulatory and commercial milestones during the company's second quarter of fiscal year 2021 ending in October.

Bellicum Secures $35M Via Equity Funding, Posts Interim Data From Early GoCAR-T Cancer Studies
06 Dec, 2021 FinancialContent

Bellicum will issue pre-funded warrants to purchase up to 20.6 million shares and accompanying warrants to purchase up to 2.06 million ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
06 Dec, 2021 FinancialContent

Gainers Adicet Bio (NASDAQ:ACET) stock increased by 37.85% to $13.51 during Monday's pre-market session. The market ...

Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
06 Dec, 2021 Yahoo! Finance

- Confirmed partial response observed in one patient in first cohort of metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 - - Favorable safety profile observed in initial dose cohort of BPX-603 in HER2+ solid tumors - - Financing expected to extend cash runway through mid-2023 and will be used to fund ongoing GoCAR-T clinical development programs - HOUSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing

Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
04 Nov, 2021 Yahoo! Finance

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief Development Officer effective December 1, 2021 - HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the third quarter 2021 and provided an opera

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
27 Oct, 2021 FinancialContent

Gainers Bio-Path Holdings (NASDAQ:BPTH) shares moved upwards by 9.69% to $5.43 during Wednesday's pre-market ...

5 Value Stocks In The Healthcare Sector
06 Sep, 2021 FinancialContent

What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
03 Sep, 2021 FinancialContent
54 Biggest Movers From Yesterday
02 Sep, 2021 FinancialContent

Gainers Focus Universal Inc. (NASDAQ: FCUV) shares climbed 278% to close at $19.28 on Wednesday. The stock started trading on ...

38 Stocks Moving In Wednesday's Mid-Day Session
01 Sep, 2021 FinancialContent

Gainers Focus Universal Inc. (NASDAQ: FCUV) shares jumped 108.2% to $10.62. The stock started trading on Nasdaq Capital Market ...

Why Is Bellicum Stock Moving Higher On Wednesday?
01 Sep, 2021 FinancialContent

Bellicum Pharmaceuticals Inc(NASDAQ: BLCM) andThe University of Texas MD Anderson Cancer Centerhaveannounced ...

Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch
01 Sep, 2021 FinancialContent
12 Health Care Stocks Moving In Tuesday's After-Market Session
24 Aug, 2021 FinancialContent

Gainers Regencell Bioscience (NASDAQ:RGC) stock rose 51.24% to $23.14 during Tuesday's after-market session. Regencell Bioscience's ...

Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update
12 Aug, 2021 FinancialContent
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
26 Jul, 2021 FinancialContent
Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch
28 Jun, 2021 FinancialContent
Should I Avoid Bellicum Pharmaceuticals Inc (BLCM)?
13 Jun, 2021 Yahoo! Finance

As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the fourth quarter of 2019. A significant number of hedge funds continued their strong […]

12 Health Care Stocks Moving In Wednesday's After-Market Session
09 Jun, 2021 FinancialContent

Gainers Enzo Biochem (NYSE:ENZ) stock increased by 8.49% to $3.45 during Wednesday's after-market session. Today's trading volume for ...

12 Health Care Stocks Moving In Wednesday's Intraday Session
26 May, 2021 FinancialContent

Gainers Owens & Minor (NYSE:OMI) shares rose 25.47% to $40.66 during Wednesday's regular session. As of 12:31 ...

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks
20 May, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update
17 May, 2021 FinancialContent
31 Stocks Moving in Thursday's Pre-Market Session
01 Apr, 2021 FinancialContent

Gainers Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) rose 44.4% to $10.73 in pre-market trading after the company, and EMC Pharma, ...

The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO
31 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

12 Stocks Moving In Tuesday's After-Hours Session
30 Mar, 2021 FinancialContent

Gainers Equillium (NASDAQ: EQ) shares are trading higher after the company announced "favorable" topline data from the ...

Bellicum Reports Fourth Quarter 2020 Financial Results and Provides Operational Update
30 Mar, 2021 FinancialContent
Bellicum Pharmaceuticals, Inc. to Host Earnings Call
30 Mar, 2021 Yahoo! Finance

NEW YORK, NY / ACCESSWIRE / March 30, 2021 / Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 30, 2021 at 5:00 PM Eastern Time.

The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
30 Mar, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Earnings Scheduled For March 30, 2021
30 Mar, 2021 FinancialContent

Companies Reporting Before The Bell • Academy Sports (NASDAQ:ASO) is likely to report quarterly earnings at $0.52 per ...

Bellicum Pharmaceuticals, Inc (BLCM) is a NASDAQ Common Stock listed in , ,

970x250